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http://dx.doi.org/10.1016/j.ccell.2014.11.025SUMMARYTransforming growth factor b (TGF-b) functions as a tumor suppressor in premalignant cells but as a
metastasis promoter in cancer cells. The dichotomous functions of TGF-b are proposed to be dictated by
different partners of its downstream effector Smads. However, the mechanism for the contextual changes
of Smad partners remained undefined. Here, we demonstrate that 14-3-3z destabilizes p53, a Smad partner
in premalignant mammary epithelial cells, by downregulating 14-3-3s, thus turning off TGF-b’s tumor
suppression function. Conversely, 14-3-3z stabilizes Gli2 in breast cancer cells, andGli2 partnerswith Smads
to activate PTHrP and promote TGF-b-induced bone metastasis. The 14-3-3z-driven contextual changes of
Smad partners from p53 to Gli2 may serve as biomarkers and therapeutic targets of TGF-b-mediated cancer
progression.INTRODUCTION
TGF-b manifests multifunctional and sometimes dichotomous
roles in numerous biological processes, such as embryonic
stem cell self-renewal and differentiation, homeostasis of
differentiated mammalian cells, and different stages of cancer
progression. In premalignant cells, TGF-b is primarily a tumor
suppressor that inhibits cell proliferation or induces apoptosis
(Massague´, 2008). In the later stages of cancer progression,
however, TGF-b functions as a metastasis promoter by inducing
epithelial-mesenchymal transition (EMT), leading to increasedSignificance
TGF-b’s critical role in cancer hasmotivated numerous efforts t
some of which have been clinically tested. However, TGF-b’s d
jor obstacles for effective TGF-b-targeting therapies because
cytostatic function in normal tissues. This study identified 14-3-
sor to metastasis promoter by altering Smad partners from p5
and downstream Smad partners could serve as (i) biomarkers f
istration and (ii) therapeutic targets to selectively block TGF-b s
sor function in normal tissues.
Cinvasion of cancer cells, and also by inducing genes that
facilitate metastatic colonization of secondary organ sites
(Massague´, 2008). Although the opposing functions of TGF-b
in early- versus late-stage cancer have been known for decades,
how and when TGF-b switches its functional roles are long-
standing questions with no clear answer. TGF-b binds to its re-
ceptor, TGFbR1/2, on the cell membrane and induces a signaling
cascade by phosphorylating Smad2/3. Phosphorylated Smad2/
3 forms a complex with Smad4 and translocates from the cyto-
plasm to the nucleus to activate the transcription of downstream
targets. An emerging notion is that the unique cellular contextoward developing TGF-b-targeting anti-cancer therapeutics,
ichotomous roles during cancer development have beenma-
systemic inhibition of TGF-b signaling also blocks TGF-b’s
3z as amolecular switch turning TGF-b from tumor suppres-
3 in premalignant cells to Gli2 in cancer cells. Thus, 14-3-3z
or patient selection and timing of anti-TGF-b therapy admin-
ignaling in cancer without impeding TGF-b’s tumor suppres-
ancer Cell 27, 177–192, February 9, 2015 ª2015 Elsevier Inc. 177
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(e.g., Smad binding partners and their modifiers) dictates the
complicated and even converse biological responses to TGF-b
(Massague´, 2012). However, which specific Smad partners
determine TGF-b’s tumor suppressor versus metastasis pro-
moter functions is unclear. More importantly, what factor(s) trig-
gers the change of Smad partners in early- versus late-stage
cancer is also unclear.
The critical role of TGF-b in cancer, especially in the process
of metastasis, has spurred the development of antagonists
that target TGF-b signaling as cancer therapeutics (Akhurst
and Hata, 2012). Disappointingly, many of the current TGF-b-tar-
geting drugs showed limited clinical efficacy. Considering the
opposing functions of TGF-b in cancer development (Massague´,
2008, 2012), it is not surprising that general inhibition of the
TGF-b pathway may have deleterious consequences (Bierie
and Moses, 2009). Inhibiting TGF-bmay accelerate the progres-
sion of preneoplastic lesions in which TGF-b still acts as a tumor
suppressor. For example, conditional knockout of Tgfbr2, which
encodes the type II TGF-b receptor (TGFbR2), in the mammary
gland of mice expressing the polyoma viral middle T antigen
(PyVmT) at puberty before mammary tumors are established
resulted in shortened tumor latency and increased pulmonary
metastases (Forrester et al., 2005). In contrast, a short induction
of TGF-b expression after mammary tumors were established
in PyVmT mice accelerated metastatic progression (Muraoka-
Cook et al., 2004). Thus, it is essential to identify the disease
stage at which patients will benefit from TGF-b antagonists
and to develop biomarkers to guide the selection of patients
for TGF-b-targeting therapies and the evaluation of therapeutic
efficacy.
RESULTS
14-3-3z Inhibits TGF-b Cytostatic Program by
Downregulation of 14-3-3s, p53, and p21
To understand how TGF-b functions are governed during
different disease stages, we first used TGF-b-responsive cell
models representing distinct breast disease stages. Since 14-
3-3z enhances TGF-b signaling and induces early transformation
and EMT of human mammary epithelial cells (HMECs) (Lu
et al., 2009), we used nontransformed MCF10A HMECs stably
transfected with a control vector (10A.Vec) or 14-3-3z cDNA
(10A. z). In 3D culture, the 10A.Vec cells produced normal acini,Figure 1. 14-3-3z Inhibits TGF-b Cytostatic Program by Downregulatio
(A) Reverse phase protein array (RPPA) analysis of 10A.Vec and 10A.z cells trea
(B and C) Immunoblotting (IB) (B) and quantitative reverse transcriptase PCR (qR
vehicle () or 5 ng/ml TGF-b (+) for 2 hr.
(D) Cell growth inhibition assay analysis of 10A.Vec or 10A.z cells treated with 5
(E) IB of p21 in p21-knockdown MCF10A cells (10A.shp21-233 and 10A.shp21-5
(F) Cell growth inhibition assay analysis of 10A.shCtrl or 10A.shp21 cells treated
(G) Immunoprecipitation (IP) of Smad2 and IB analysis of p53, p-Smad2 in indica
(H) Gene expression profiling of 10A.P, 10A.Vec, and 10A.z cells by cDNA micro
(I and J) qRT-PCR (I) and IB (J) analysis of 14-3-3s expression in 10A.P, 10A.Vec
(K) IB analysis of 14-3-3s and p53 expression in 14-3-3s-knockdown cells comp
(L) Cell growth inhibition assay analysis of 10A.shs (-128 and -130) cells compar
(M) IB of indicated proteins of TGF-b cytostatic program in 10A.shCtrl and 10A.s
(N) IB analysis of protein expressions of TGF-b’s cytostatic program in indicated
(O) BrdU incorporation assay analysis of TGF-b-treated 10A.Vec, 10A.z, and 10A
Error bars represent SD, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
Cwhile the 10A.z cells generated atypical ductal hyperplasia
(ADH)-like acini. Initially, we performed reverse phase protein
array (RPPA) proteomic profiling of 10A.Vec and 10A.z cells
cultured with fresh media containing TGF-b or vehicle for 2 hr
(Figure 1A and Figure S1A available online). 14-3-3z inhibited
TGF-b-induced expression of p21, a key effector of TGF-b’s
cytostatic program, but not other known effectors (e.g., p27/
Kip1) (Massague´, 2008). Compared to 10A.Vec cells, both the
basal and TGF-b-induced p21 protein and mRNA expression
were inhibited in 10A.z cells (Figures 1A–1C). Consequently,
TGF-b inhibited the proliferation and immediate entry into the
S phase of 10A.Vec cells, but not 10A.z cells (Figures 1D and
S1B–S1D). Similar results were found in MCF12A HMECs (Fig-
ures S1E and S1F), indicating that 14-3-3z blocks the prolifera-
tion-suppression function of TGF-b in HMECs. To test whether
p21 is the key executor of TGF-b’s cytostatic tumor suppression
function in these HMECs, we knocked down p21 in both
MCF10A and MCF12A cells (Figures 1E and S1G). Indeed, p21
knockdown abrogated TGF-b’s proliferation suppression func-
tion in both cell lines (Figures 1F, S1H, and S1I), highlighting
that p21 is the key executor required for TGF-b’s cytostatic
tumor suppression function and 14-3-3z-mediated p21 downre-
gulation can block TGF-b’s cytostatic program in HMECs.
TGF-b-induced p21 expression in HMECs requires specific
cellular context-dependent Smad partners, e.g., p53 (Corde-
nonsi et al., 2003) or FOXO3a (Mun˜oz-Espı´n et al., 2013). We
found that p53 complexed with Smad2 in TGF-b-treated
10A.Vec and 12A.Vec cells, while FOXO3a did not bind to Smads
(Figures 1G and S1J–S1L). Interestingly, 14-3-3z downregulated
p53 and diminished p53’s interaction with Smad2 in both 10A.z
and 12A.z cells (Figures 1G and S1J). Furthermore, silencing p53
in both MCF10A and MCF12A cells reduced TGF-b-induced
p21 expression (Figures S1M and S1N), indicating that p53 is
the contextual determinant of Smads for TGF-b-induced p21
expression in these HMECs and that 14-3-3z inhibits TGF-
b-induced p21 expression by reducing p53 level.
Since p53 downregulation reduces TGF-b-induced p21
expression and cytostatic function, and p53 regulation occurs
atmultiple levels (Golubovskaya andCance, 2013), we dissected
the mechanisms of p53 downregulation by 14-3-3z. We
compared gene expression profiles of 3D-cultured 10A.Parental
(10A.P), 10A.Vec, and 10A.z cells by cDNA microarray.
We discovered that 14-3-3s (SFN), a tumor suppressor thatn of 14-3-3s, p53, and p21
ted with vehicle () or 5 ng/ml TGF-b (+) for 2 hr.
T-PCR) (C) analysis of p21 expression in 10A.Vec and 10A.z cells treated with
ng/ml TGF-b.
35) and control cells transfected with control shRNA (10A.shCtrl).
with 5 ng/ml TGF-b.
ted cells treated with vehicle () or 10 ng/ml TGF-b (+) for 2 hr.
array. Heatmap depicts 14-3-3z-induced top gene alterations. *SFN.
and 10A.z cells.
ared to 10A.P and 10A.shCtrl cells.
ed to 10A.shCtrl cells treated with 5 ng/ml TGF-b.
hs-128 cells treated with vehicle () or 5 ng/ml TGF-b (+) for 2 hr.
cells.
.z.s cells.
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Figure 2. 14-3-3z Represses 14-3-3s Transcription by Cytosolic Sequestration of YAP1
(A) Luciferase activity assay of 14-3-3s promoter (-1221)-driven luciferase (pGL3-14-3-3s) expression in indicated cells 48 hr posttransfection. The pRL-TK
vector was used as an internal control.
(B) Schematic representation of sequential deletions of the 14-3-3s promoter cloned in the upstream of the luciferase reporter (top) and mutations (M1 to M5) of
putative transcription factor binding sites in the -922 to -741 region of the 14-3-3s promoter (bottom).
(C) Relative luciferase activity driven by sequential deletions of 14-3-3s promoter (-1221, -922, and -741) in 10A.Vec and 10A.z cells.
(D) Relative luciferase activity driven by binding site mutations of 14-3-3s promoter (-922) in 10A.Vec cells.
(E) ChIP assay of YAP1 binding to 14-3-3s promoter in 10A.Vec and 10A.z cells with indicated antibodies.
(legend continued on next page)
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stabilizes p53 protein through cytoplasmic retention of the E3
ligase for p53-MDM2 (Lee and Lozano, 2006), was downregu-
lated by 14-3-3z (Figure 1H). 14-3-3s downregulation by 14-
3-3z was confirmed at both mRNA and protein levels in
both10A.z and 12A.z cells (Figures 1I, 1J, S1O, and S1P). Addi-
tionally, overexpression of 14-3-3z reduced 14-3-3s level,
whereas knockdown of 14-3-3z increased 14-3-3s level in mul-
tiple human breast cancer cell lines (Figure S1Q), suggesting that
14-3-3z-mediated regulation of 14-3-3s is common in breast
cancer. Furthermore, silencing of 14-3-3s reduced p53 level
and blocked TGF-b-induced p21 expression and proliferation
suppression in both MCF10A and MCF12A cells (Figures 1K–
1M and S1R–S1U). Conversely, reintroducing 14-3-3s rescued
p53 expression and restored TGF-b-induced p21 expression
and cytostatsis in 10A.z cells (Figures 1N and 1O). This indicated
that 14-3-3z and 14-3-3s play opposing roles in regulating TGF-
b-induced p21 expression and proliferation suppression and
14-3-3z downregulated p53 primarily by repressing 14-3-3s.
Altogether, 14-3-3z-mediated 14-3-3s downregulation led to
loss of p53, the specific Smad partner for TGF-b-induced p21
expression in HMEC, and, consequently, switched off TGF-b’s
cytostatic tumor suppression function in premalignant cells.
14-3-3z Represses 14-3-3s Transcription by Cytosolic
Sequestration of YAP1
To investigate how 14-3-3z downregulates 14-3-3s expression,
we first compared 14-3-3s mRNA stability and its promoter
methylation between 10A.z and 10A.Vec cells and found no sig-
nificant difference (Figures S2A and S2B). Further, DNA methyl-
ation inhibitor (5-Aza-20-deoxycytidine) treatment did not restore
14-3-3s expression in 10A.z cells (Figure S2C). This suggested
that 14-3-3z did not affect 14-3-3s mRNA stability or its epige-
netic regulation but instead inhibited its transcription. Indeed,
when we transfected a luciferase reporter driven by the 14-3-
3s promoter into 10A.parental (10A.P), 10A.Vec, and 10A.z cells,
we found that 14-3-3s promoter activity was repressed in 10A.z
cells compared to 10A.P and 10A.Vec cells (Figure 2A).
To uncover the specific DNA element in the 14-3-3s promoter
responsible for 14-3-3z-mediated trans-repression, we gener-
ated a series of 14-3-3s promoter 50-deletion driving lucif-
erase-reporter constructs (Figure 2B). We found that a 181 bp
(-922 bp to -741 bp) promoter region was mostly responsible
for 14-3-3s transcription, which was repressed by 14-3-3z
(Figure 2C). TESS (http://www.cbil.upenn.edu/tess) analysis
revealed several putative transcription factor binding sites within
this 181 bp region (Figure S2D). Mutation analyses (M1–M5)
revealed that the M2 site, a predicted binding site for the YAP1
transcriptional coactivator, was primarily responsible for 14-3-
3s transactivation (Figures 2B, 2D, and S2E). Indeed, YAP1
bound efficiently to the 14-3-3s promoter in 10A.Vec cells,(F) IP of HA-14-3-3z and IB analysis of indicated proteins in 10A.z cells.
(G) IP of HA-14-3-3z and IB analysis of indicated proteins in 12A.Vec and 12A.z
(H) Immunofluorescence staining analysis of 14-3-3z and YAP1 in 10A.Vec and 1
10A.z cells. Scale bars represent 10 mm.
(I) Cell fractionation of 10A.Vec and 12A.Vec or 10A.z and 12A.z cells and IB of
nuclear marker.
(J and K) IB (J) and qRT-PCR (K) analysis of 14-3-3s expression in YAP1-knockd
Error bars represent SD, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
Cwhereas the binding was significantly inhibited by 14-3-3z over-
expression (Figure 2E). This inhibitionwas due to 14-3-3z binding
to and sequestering phospho-YAP1 outside of the nucleus (Fig-
ures 2F–2I and S2F and S2G), while 14-3-3z had no significant
effect on YAP1 protein level (Figure S2H). Moreover, 14-3-3s
protein and mRNA levels were reduced in YAP1-knockdown
cells (Figures 2J and 2K), indicating that YAP1 is a critical
transactivator of 14-3-3s in HMECs, while 14-3-3z binds to
phospho-YAP1, sequesters it in the cytoplasm, and prevents it
from transactivating 14-3-3s.
14-3-3z-Linked Gene Signature Is Associated with
TGF-b-Regulated Genes in Bone Metastasis
The above findings indicate that 14-3-3z inhibits the TGF-
b-induced cytostatic program in premalignant HMECs by cyto-
plasmic retention of YAP1, thereby repressing 14-3-3s that leads
to downregulation of p53, a Smad partner for p21 transcription.
To explore whether 14-3-3zmay also switch on TGF-b’s metas-
tasis promoter function in cancer cells, we generated derivatives
of MDA-MB-231, a highly metastatic human breast cancer cell
line that expresses a high level of 14-3-3z, with either 14-3-3z
shRNA (231.shz) or control shRNA (231.shCtrl) (Figure 3A). First,
cDNAmicroarray analysis of 231.shCtrl cells treated with vehicle
or TGF-b revealed a TGF-b-induced 84-gene signature (Fig-
ure S3A). Analyses of these TGF-b-induced genes in the data
set available in the Gene Expression Omnibus (GEO) database
under accession number GSE14020, generated from metastatic
tumors of human breast cancers to the major metastatic organ
sites (Zhang et al., 2009), revealed that many of these genes
were expressed at a higher level in bone metastases than in
metastases to other organs (Figures S3B and S3C). Second,
comparing 231.shz and 231.shCtrl without TGF-b treatment
revealed an 85-gene 14-3-3z signature, which was also highly
expressed in breast cancer bone metastases compared to
metastases to other organs (Figures 3B and 3C). Consistently,
a 14-3-3z-induced gene signature generated from cDNA micro-
arrays of 10A.z compared to 10A.Vec cells was also predomi-
nantly expressed in bone metastases (Figures 1H and 3D). To
see whether patients with 14-3-3zhigh breast cancers are prone
to development of bone metastasis, univariate analysis was per-
formed on a cohort of 253 breast cancer patients with clinically
annotated data for development of bone metastasis in 5 years
(EMC-286 data set) (Bos et al., 2009). It revealed that patients
with 14-3-3zhigh breast tumors had a significantly (p = 0.034)
reduced bone metastasis-free survival (Figure 3E). Additionally,
among patients who developed bone metastasis, patients with
14-3-3zhigh breast tumors have a significantly earlier bonemetas-
tasis onset than those with 14-3-3z low-expressing tumors (p <
0.05; Figure S3D). Together, these data indicated that elevated
14-3-3z is associated with breast cancer bone metastases.cells. IP Ab, antibodies used for IP.
0A.z cells. Arrows indicate colocalization of 14-3-3z and YAP1 in the cytosol of
indicated proteins. Tubulin serves as cytoplasmic marker; Lamin B serves as
own cells compared to 10A.shCtrl or 12A.shCtrl cells.
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Figure 3. 14-3-3z-Linked Gene Signature Is Associated with TGF-b-Regulated Genes in Bone Metastasis
(A) IB of indicated proteins in 231.shCtrl and 231.shz cells treated with vehicle or TGF-b (5 ng/ml, 2 hr).
(B) Expression heatmap of 14-3-3z 85-gene signature in 231.shCtrl cells compared to 231.shz cells.
(C) Significance score distribution of 14-3-3z signature from MDA-MB-231 cells in breast cancer metastases of indicated organs.
(legend continued on next page)
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Finally, the 231.shz cells with 14-3-3z knockdown manifested
a partially impaired TGF-b-induced gene signature (Figure 3F),
and many of these impaired genes were highly expressed in
bone metastasis (Figure 3G). This suggested that 14-3-3z may
switch on TGF-b’s bone metastasis promoter function by regu-
lating TGF-b’s transcriptomic profile in breast cancer.
14-3-3z Promotes TGF-b-Induced Breast Cancer Bone
Metastasis by Activating PTHrP
After we found that 14-3-3z-linked genes were associated with
TGF-b’s bone metastasis promoter function in breast cancer,
we next set to determine whether 14-3-3z plays an essential
role in TGF-b-mediated bone metastasis. Using 231-1566 cells,
a MDA-MB-231 bone metastasis derivative that expresses GFP
and luciferase (Khotskaya et al., 2014), we introduced either
14-3-3z shRNA (1566.shz) or control shRNA (1566.shCtrl) (Fig-
ure S4A, left). We then compared their bone metastasis potential
by injection into the left ventricle of nudemice. Mice injected with
1566.shz had significantly longer bone metastasis-free survival
compared to mice in the 1566.shCtrl group, even though
1566.shCtrl and 1566.shz cells showed nodiscernable difference
in cell proliferation in vitro (Figures 4A, 4B, and S4B). Biolumines-
cence imaging (BLI) revealed that 100% of mice injected with
1566.shCtrl cells developed bone metastases by 35 days, when
only 25% of mice injected with 1566.shz cells had bone lesions
(Figure 4A), and these bone lesions had an incomplete 14-3-3z
knockdown (Figure 4B). Similar trends were observed in another
derivative (BoM-1833) fromMDA-MB-231-induced bone metas-
tasis (Kang et al., 2003; Zhang et al., 2009) (Figures S4A–S4D).
Breast cancer cell growth in the bone is a critical step for bone
metastasis formation. To further investigate whether 14-3-3z
promotes breast cancer cell growth in the bone, we injected
GFP- and luciferase-labeled 231.shCtrl (14-3-3z high) and
231.shz (14-3-3z low) cells intratibially into nudemice to compare
their bone colonization ability. Mice injected with 231.shz cells
showed significantly prolonged bone tumor-free survival and de-
layed outgrowth of bone tumors compared to the 231.shCtrl
group (Figures 4C and 4D). The difference in bone tumor burden
between the 231.shCtrl and 231.shz groups was also clearly
demonstrated by BLI, X-ray analysis, and hematoxylin and eosin
(H&E) and 14-3-3z immunohistochemical (IHC) staining (Fig-
ure 4D). Additionally, we examined whether 14-3-3z plays an
essential role in TGF-b-mediated bone metastasis outgrowth in
a syngeneicmousemodel using the highlymetastatic 4T1mouse
mammary tumor cell line that expresses a high level of 14-3-3z.
We generated 4T1 derivatives transfected with either 14-3-3z
shRNA (4T1.shz) or control shRNA (4T1.shCtrl) (Figure S4A, right)
and injected 4T1.shCtrl and 4T1.shz cells expressing GFP and
luciferase intratibially into BALB/c mice. Mice injected with(D) Significance score distribution of 14-3-3z-induced gene signature from MCF
indicates the significance level of p = 0.0001.
(E) Kaplan-Meier curves for bone metastasis-free survival according to 14-3-3z ex
was calculated based on log rank test.
(F) Gene expression heatmap of 34 TGF-b-induced genes inhibited by 14-3-3z k
(G) Significance score distribution of TGF-b-induced bone metastasis genes (
metastases of indicated organs (accession number GSE14020).
Box plots show the distribution of scores. The thick line in the middle of the box s
lower (first) quartile values, respectively, and the top and bottom of the line show
C4T1.shz cells had significantly reduced bone tumor burdens
with smaller osteolytic lesions compared to mice injected with
the 4T1.shCtrl cells as quantified by the BLI signal, X-ray anal-
ysis, H&E and 14-3-3z IHC staining, although 4T1.shCtrl and
4T1.shz cells showed no apparent difference in cell proliferation
in vitro (Figures S4E–S4G). Overall, these data demonstrated
that elevated 14-3-3z expression in human breast cancer and
mammary tumor cells with increased TGF-b activity promotes
their outgrowth in the bone and increases bone metastasis.
TGF-b promotes breast cancer bone metastasis via a ‘‘vicious
cycle’’: briefly, osteoclast-induced osteolysis releases TGF-b in
the bone microenvironment, stimulating metastatic cancer cell
proliferation and secretion of parathyroid hormone-related pro-
tein (PTHrP), which stimulates osteoblasts to release RANKL,
which in turn promotes osteoclast maturation and function, ulti-
mately releasing more TGF-b (Mundy, 2002; Padua and Mas-
sague´, 2009). To investigate whether and how 14-3-3z promotes
bone metastasis via TGF-b’s ‘‘vicious cycle,’’ we cocultured
231.shCtrl and 231.shz cells with preosteoclasts (RAW264.7)
and osteoblasts (MC3T3) under vehicle or TGF-b treatment (tri-
ple coculture). We examined osteoclast maturation and breast
cancer cell proliferation since both osteolysis by mature osteo-
clasts and breast cancer cell growth in the bone are critical
events for bone metastasis formation. TGF-b treatment of triple
co-cultured 231.shCtrl cells stimulated RAW264.7 preosteoclast
differentiation and maturation, indicated by tartrate-resistant
acid phosphatase-positive (TRAP+) staining, a marker of mature
osteoclasts; this was inhibited by 14-3-3z knockdown (Figures
4E and 4F). Meanwhile, proliferation of 231.shCtrl, but not
231.shz, was increased by TGF-b treatment in triple coculture
(Figures 4G and S4H). Notably, osteoclast maturation and
231.shCtrl and 231.shz cell proliferation were similar in vehicle-
treated cocultures and in TGF-b-treated single cultures (Figures
4E–4G, S4H, and S4I), indicating that 14-3-3z does not itself
affect osteoclast maturation or cancer cell proliferation, but
rather modulates TGF-b’s effects on the bone microenviron-
ment. Collectively, 14-3-3z in breast cancer cells promotes
TGF-b-induced breast cancer cell proliferation and osteo-
clast maturation, thereby enhancing TGF-b-induced osteolysis,
breast cancer outgrowth, and bone metastasis.
Several of TGF-b’s downstream targets, including PTHrP, IL-
11, and Jagged-1, can promote breast cancer metastasis to,
and survival in, the bone microenvironment (Kang et al., 2003;
Sethi et al., 2011; Waning and Guise, 2014). To identify which
TGF-b downstream target(s) mediates 14-3-3z-driven bone
metastasis promotion in vivo, we measured PTHrP, IL-11, and
Jagged-1 protein levels in the bone lesions. We found that
only the expression of PTHrP, and not IL-11 or Jagged-1, was
reduced in 1566.shz and 231.shz bone metastases compared10A cells in metastases of breast cancer at different organs. Red dashed line
pression level in a subset of 253 breast tumors in the EMC-286 cohort. p value
nockdown.
10 of the genes identified in Figure 3F) inhibited by 14-3-3z knockdown in
hows median value. The top and bottom of the box represent upper (third) and
maximum and minimum values, respectively. See also Figure S3.
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Figure 4. 14-3-3z Promotes TGF-b-Induced Breast Cancer Bone Metastasis by Activating PTHrP
(A) Kaplan-Meier survival analysis of mice injected intracardially with 1 3 105 1566.shCtrl or 1566.shz cells.
(B) Representative BLI, X-ray, and H&E images of bonemetastatic lesions ofmice in (A) at the indicated time. 14-3-3z expression level was shown by IHC staining.
Arrows indicate osteolytic bone lesions. Abbreviations: T, tumor; B, bone tissue; BLI, bioluminescence imaging. Scale bars represent 50 mm.
(C) Kaplan-Meier survival analysis of mice injected intratibially with 231.shCtrl or 231.shz cells.
(D) Representative BLI, X-ray, and H&E images of bone lesions (day 49) of mice in (C). 14-3-3z expression level was shown by IHC staining. Arrows indicate
osteolytic bone lesions. Abbreviations: T, tumor; B, bone tissue. Scale bars represent 50 mm.
(legend continued on next page)
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to 1566.shCtrl and 231.shCtrl metastases, respectively (Figures
4H, 4I, S4J, and S4K). Similarly, PTHrP expression was also low
in 4T1.shz bone lesions compared to 4T1.shCtrl bone metasta-
ses (Figures S4L and S4M). Furthermore, TGF-b-induced PTHrP
mRNA expression was inhibited by 14-3-3z knockdown in
1566.shz, 231.shz, and 4T1.shz cells (Figures 4J, S4N, and
S4O), indicating that 14-3-3z contributes to TGF-b-induced
PTHrP mRNA expression in breast cancer cells.
14-3-3z Enhances TGF-b-Induced PTHrP mRNA
Expression by Stabilizing Gli2
PTHrP is a key mediator of TGF-b’s bone metastasis program,
and TGF-b has been reported to induce PTHrP mRNA expres-
sion primarily through canonical Smad signaling (Kakonen
et al., 2002). Smads are known to transcriptionally upregulate
Gli2, which in turn transactivates PTHrP mRNA expression
(Dennler et al., 2007). This TGF-b/Smad/Gli2 signaling axis was
shown to be important for PTHrP mRNA expression and bone
metastasis (Javelaud et al., 2011). To investigate how 14-3-3z
contributes to TGF-b-induced PTHrP mRNA expression, we first
examined whether 14-3-3z affects Smad2/3 or Gli2 expression
and Smad2/3 phosphorylation. Compared to 1566.shCtrl,
231.shCtrl, or 4T1.shCtrl cells, silencing of 14-3-3z significantly
decreased Gli2 protein level in vivo and in vitro without altering
Smad2/3 expression or phosphorylation in 1566.shz, 231.shz,
and 4T1.shz cells (Figures 5A–5C and S5A–S5E). Furthermore,
overexpression of 14-3-3z in 10A.z, 12A.z, and MCF7.z cells
increased Gli2 protein levels to turn on TGF-b’s bone metastasis
program (upregulation of PTHrP) while concomitantly turning off
TGF-b’s cytostatic program (downregulation of 14-3-3s, p53,
and p21), compared to 10A.Vec, 12A.Vec, and MCF7.Vec cells
(Figures S5F and S5G). Unexpectedly, Gli2 mRNA levels were
similar between control and 14-3-3z knockdown cells with or
without TGF-b treatment (Figures S5H–S5J), indicating that the
TGF-b-induced increase of Gli2 protein in 14-3-3z overexpres-
sion cells was independent of the previously reported TGF-b/
Smad-mediated Gli2 transcription (Dennler et al., 2007). At the
protein level, 14-3-3z knockdown did not affect Gli2 translation,
but reduced protein stability by increasing proteasome-medi-
ated degradation (Figures 5D and S5K–S5M). Compared to
231.shCtrl or 4T1.shCtrl cells, Gli2 ubiquitination was increased
in 231.shz or 4T1.shz cells with 14-3-3z knockdown under TGF-b
treatment (Figures 5E and S5N–S5Q). To further dissect the
mechanism of 14-3-3z-mediated inhibition of Gli2 ubiquitination,
we compared the binding of Gli2 to its E3 ligase, b-TrCP, in TGF-
b-treated 231.shCtrl and 231.shz cells (Bhatia et al., 2006).
In 231.shCtrl cells, both endogenous Gli2 and ectopically ex-
pressedMyc-taggedGli2 bound robustly to 14-3-3z but scarcely
to b-TrCP; conversely, Gli2 binding to b-TrCP was evident in
231.shz cells, wherein Gli2 could not bind to 14-3-3z (Figures(E and F) Representative staining images (E) and quantification (F, three repeats)
cancer cells treated with vehicle or TGF-b. The arrows indicate TRAP+ mature o
(G) Quantification of indicated GFP-labeled cancer cells grown under triple cocu
10 cm plates for counting. TGF-b treatment (5 ng/ml, 6 days).
(H and I) Representative IHC images (H) and quantification (I) of PTHrP protein ex
five mice in the 231.shz group had no bone lesions and were excluded from PTH
(J) qRT-PCR analysis of PTHrP mRNA in 231.shCtrl or 231.shz cells.
Error bars represent SD, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
C5F and S5R). Additionally, GST-tagged 14-3-3z proteins effi-
ciently competed with b-TrCP for binding to Gli2 (Figure 5G),
indicating that 14-3-3z blocked Gli2 binding to b-TrCP, thereby
increasing Gli2 stability. Moreover, the MG132 treatment that
stabilized Gli2 in 231.shz also rescued TGF-b-induced PTHrP
mRNA expression (Figure 5H), indicating that Gli2 stabilization
by 14-3-3z enhances TGF-b-induced PTHrP mRNA expression.
These unexpected findings of 14-3-3z-induced Gli2 protein
stabilization in response to TGF-b differ from previously reported
TGF-b/Smad-induced Gli2 transactivation (Dennler et al., 2007).
To gain insight on how TGF-b-activated Smads cooperate with
14-3-3z-stabilized Gli2 to transactivate PTHrP in MDA-MB-231
cells, we tested whether Gli2 functioned as a Smad binding part-
ner in the same transcriptional complex. Obviously, TGF-b treat-
ment induced Gli2 binding to Smads in 231.shCtrl, but not in
231.shz cells (Figures 5I, S5S, and S5T), indicating that Gli2, sta-
bilized by 14-3-3z, is a decisive contextual determinant of Smads
for transactivation of PTHrP expression in breast cancer cells.
14-3-3z Overexpression Is Associated with the Loss of
TGF-b Tumor Suppressor Function and Gain of Its
Metastasis Promoter Functions in Patients
Our result so far indicate that 14-3-3z blocks TGF-b’s tumor sup-
pressor function by reducing 14-3-3s and p21 but switches
on TGF-b’s metastasis-promoting function by stabilizing Gli2 in
breast cancer. To determine the clinical relevance and validity
of our findings, we examined the expression of key components
of the TGF-b signaling program (Smads, YAP1, 14-3-3s, p21,
and Gli2) and their relationship with 14-3-3z in patient-derived
tissue samples. We performed IHC analysis on different stages
(40 cases each) of breast disease and cancer, including atypical
ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and
invasive ductal carcinoma (IDC), with normal breast tissue as
controls. TGF-b downstream targets p-Smad2 and p-Smad3
were positive in normal tissues and ADH, a very early stage of
breast disease, and significantly increased at the later stages
of DCIS and IDC; at the same time, total Smad2/3 levels were
positive but constant (Figures S6A–S6D). Together, these find-
ings indicated that TGF-b signaling was functional and further
activated during breast cancer initiation and progression.
Notably, increased p-Smad2 and p-Smad3 levels significantly
correlated with 14-3-3z overexpression, which started at ADH
and increased at DCIS and IDC (Figures 6A, S6E, and S6F),
indicating that 14-3-3z enhanced TGF-b/Smad signaling as we
previously reported (Lu et al., 2009).
We also found that YAP1 expression and nuclear localization
were significantly decreased relative to normal breast tissues
starting from ADH stage (Figures 6A, S6G, and S6H), which
is consistent with previous reports (Tufail et al., 2012; Yuan
et al., 2008). Moreover, 14-3-3s and p21 expression decreasedof TRAP+ mature osteoclasts culture with MC3T3 osteoblasts and 231 breast
steoclasts. Scale bars represent 200 mm.
lture. Cells were trypsinized from each triple coculture group and recultured in
pression in mouse bone lesions. Note that four mice in the 1566.shz group and
rP protein analysis. Scale bars represent 50 mm.
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Figure 5. 14-3-3z Enhances TGF-b-Induced PTHrP mRNA Expression by Stabilization of Gli2
(A and B) Representative IHC images (A) and quantification (B) of Gli2 expression in the indicated mouse bone lesions. Scale bar represents 50 mm.
(C) IB analysis of Gli2 expression in 231.shCtrl and 231.shz (-4 and -5) cells treated by vehicle or TGF-b (5 ng/ml).
(D) IB analysis of Gli2 protein in 231.shCtrl and 231.shz cells treated with TGF-b (5 ng/ml) and MG132 (10 mM) for indicated times.
(E) IP of Myc-Gli2 and IB analysis of Gli2 ubiquitination in indicated cells treated with TGF-b (5 ng/ml) and MG132 (10 mM).
(F) IP of Myc-Gli2 and IB analysis of indicated proteins in cells treated with TGF-b (5 ng/ml) and MG132 (10 mM).
(G) IP of Myc-Gli2 and IB analysis of indicated proteins. 231.shz cells were transfected with Myc-Gli2 and treated with TGF-b (5 ng/ml) and MG132 (10 mM). Cell
lysates were incubated with or without GST (1 mM) or GST-14-3-3z (200 nM or 1 mM) overnight.
(H) qRT-PCR analysis of PTHrP mRNA level in indicated cells with indicated treatment.
(I) IP of Smad2 and IB analysis of indicated proteins in indicated cells.
IP Ab, antibodies used for IP. Error bars represent SD, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.significantly starting at ADH stage and nuclear YAP1, 14-3-3s,
and p21 levels inversely correlated with 14-3-3z overexpression
during breast cancer progression (Figures 6A–6C and 6E). In
contrast, Gli2 was significantly increased starting at the ADH
stage and correlated with 14-3-3z overexpression at IDC stage
(Figures 6A, 6D, and 6E).186 Cancer Cell 27, 177–192, February 9, 2015 ª2015 Elsevier Inc.DISCUSSION
TGF-b’s complicated biological responses have been proposed
to be governed by the different cellular contextual determinants
of Smads (Massague´, 2012), including a wide-ranging comple-
ment of DNA-binding transcription factors, involving p53 and
members of the bHLH, Forkhead box (e.g., Foxo3a), and zinc
finger protein families (e.g., Gli2) in different cells and various bio-
logical processes (Cordenonsi et al., 2003; Feng and Derynck,
2005). However, the specific Smad partners determining TGF-
b’s tumor suppressor versus metastasis promoter functions
were elusive, and the factors triggering the contextual changes
in Smad determinants are also not clear. Here, we unveiled
that (1) p53 is the critical Smad partner for TGF-b-induced p21
expression and tumor suppression in premalignant HMECs,
whereas Gli2 is the decisive Smad partner for TGF-b-induced
PTHrP expression and metastasis promotion in breast cancer
cells, and (2) 14-3-3z switches TGF-b’s function by triggering
the contextual change of Smad partners from p53 in premalig-
nant HMECs to Gli2 in breast cancer. Mechanistically, 14-3-3z
overexpression destabilizes p53 by cytoplasmic sequestration
of YAP1, leading to reduced transcription of 14-3-3s, a tumor
suppressor that stabilizes p53 protein, while 14-3-3z stabilizes
Gli2 by blocking Gli2’s binding with its E3 ligase b-TrCP (Fig-
ure 7). Therefore, our study provided answers to the long-stand-
ing questions of how and when TGF-b switches its functional
roles from a tumor suppressor to a metastasis promoter. More-
over, TGF-b has multifunctional roles in numerous biological
processes. Our study may facilitate more discoveries on cellular
events that switch the contextual determinants of Smads, which
will enable comprehensive understanding of TGF-b’s multifunc-
tional and even opposing roles not only in cancer development
but also in TGF-b’s various general biological and pathological
responses.
Previously, it was reported that 4 hr of TGF-b treatment
induced Gli2 mRNA transcription in MDA-MB-231 cells, which
subsequently transactivated PTHrP (Dennler et al., 2007). Here,
we found that TGF-b induced an immediate (in < 2 hr) increase
of Gli2 protein via 14-3-3z-mediated Gli2 stabilization, indicating
that TGF-b induces Gli2 expression at multiple levels. In addition,
we found that TGF-b-activated Smads can directly bind to Gli2
protein to upregulate PTHrP transcription. Thus, TGF-b-acti-
vated Smads can induce PTHrP expression both indirectly via
transactivating Gli2, which in turn induces PTHrP transcription,
and directly by binding to Gli2 to turn on PTHrP transcription,
which is empowered by 14-3-3z. Interestingly, 14-3-3z was
reported to bind to and stabilize b-catenin in the cytoplasm in
response to Wnt signaling (Tian et al., 2004), suggesting that
14-3-3z may regulate multiple other signaling pathways by a
similar mode of binding to and stabilizing downstream key regu-
lators of these pathways.
The 14-3-3 proteins are a family of evolutionarily conserved
and ubiquitously expressed proteins in eukaryotes with seven
mammalian isoforms: b, g, ε, h, s, t, and z. These 29-31 kDa
acidic proteins form heterodimers or homodimers to bind to
specific motifs on target proteins in a phosphorylation-depen-
dent manner, subsequently altering their subcellular locali-
zation, stability, enzymatic activity, etc. As a result, 14-3-3
proteins are involved in many important cellular processes
(Reinhardt and Yaffe, 2013). Here, we found that 14-3-3z
overexpression led to transcriptional repression of 14-3-3s.
Although in the same family, 14-3-3z and 14-3-3s have oppo-
site roles in several biological functions, including PI3K-Akt
signaling, p53 stability, cell polarity, and invasion (Danes et al.,
2008; Ling et al., 2010; Lu et al., 2009; Neal et al., 2012). AmongCthe 14-3-3 family members, 14-3-3s is known as a tumor sup-
pressor gene, which is lost in multiple types of cancer (Akahira
et al., 2004). The unique biology of 14-3-3smay be explained by
its different structure from the rest of 14-3-3 family members
(Reinhardt and Yaffe, 2013; Wilker et al., 2005). An imbalance
between 14-3-3s and other 14-3-3 family members may result
in cancer or other disorders. However, the mechanism under-
lying the imbalance between 14-3-3s and other 14-3-3 family
members has always been unclear. Here, we revealed that
14-3-3z represses 14-3-3s by sequestrating its transcription
coactivator YAP1 outside of the nucleus, suggesting a critical
role for YAP1 in maintaining the homeostasis of the 14-3-3
family in HMECs.
14-3-3s and 14-3-3z have opposing functions on p53. 14-3-
3s can interact with and stabilize p53 by blocking Mdm2-medi-
ated p53 ubiquitination and nuclear export (Yang et al., 2003,
2007). We found that 14-3-3z can destabilize p53 protein
partially through PI3K-Akt activation of Mdm2 (Danes et al.,
2008) and by downregualtion of 14-3-3s. As restoration of 14-
3-3s fully recovered p53 expression in 10A.z cells, 14-3-3s is
likely amajor regulator of p53 stability, while 14-3-3z destabilizes
p53 primarily through downregulating 14-3-3s.
The Hippo-YAP pathway plays very important roles in control-
ling organ size and tumorigenesis, and activation of the Hippo
pathway leads to phosphorylation and inhibition of transcrip-
tional coactivators, including YAP (Harvey et al., 2013). There
have been controversial reports on the role of YAP1 in cancer
development (Bertini et al., 2009; Luk and Guan, 2014; Zhao
et al., 2011). Initially, the YAP1 gene was found to be amplified
in human hepatocellular carcinomas and induce transformation
(Zender et al., 2006). Recently, however, YAP1 was defined as
an apoptosis-inducing tumor suppressor that is silenced in mul-
tiple types of cancer (Bai et al., 2013; Barry et al., 2013; Cottini
et al., 2014; Lapi et al., 2008; Yu et al., 2013). Moreover, mam-
mary epithelia-specific hyperactivation of YAP1 in transgenic
mice did not increase mammary cell proliferation or induce
tumors (Chen et al., 2014), indicating that YAP1 does not have
an oncogenic function in mammary glands. Here, we found
that nuclear YAP1 transactivates the 14-3-3s tumor suppressor
gene in HMECs. Thus, 14-3-3s is a target gene of YAP1 and
mediates YAP1 tumor suppressor function in HMECs. As a tran-
scriptional coactivator, YAP1 has oncogenic functions when it
binds to TEA domain family transcription factors (Harvey et al.,
2013), while it functions as a tumor suppressor when bound to
p73 or p53BP2 (Basu et al., 2003; Cottini et al., 2014; Fausti
et al., 2013). In future studies, it will be interesting to identify
the partner transcription factors of YAP1 for 14-3-3s transactiva-
tion and to test the functional role of cytosolic YAP1 retained by
14-3-3z in HMECs.
YAP1 nuclear localization was inhibited by 14-3-3z both in tis-
sue samples and in cell models. Previously, it was found that
YAP1 expression is downregulated in breast cancers compared
to normal breast tissues (Tufail et al., 2012; Yuan et al., 2008).
Here, we also found that YAP1 protein levels in breast tissues
were decreased as cancer progressed and 14-3-3z expression
increased. However, YAP1 protein levels in 10A.z and 12A.z cells
were similar to that in their control cells. This suggested that
other 14-3-3z-independent mechanisms may regulate YAP1
protein stability (Lapi et al., 2008) or YAP1 protein translationancer Cell 27, 177–192, February 9, 2015 ª2015 Elsevier Inc. 187
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Figure7. Diagramof14-3-3z-DrivenContex-
tual Changes of Smad Partners from p53 in
Premalignant Cells to Gli2 in Cancer Cells
In premalignant human MECs, YAP1 is a critical
transcription coactivator for 14-3-3s, and 14-3-3s
stabilizes p53, a Smad partner for transactivation
of p21, which is the key executor of TGF-b’s
cytostatic and tumor suppression program (left). In
breast cancer cells, Gli2 is a Smad partner for
transactivation of PTHrP, which is a key facilitator
of TGF-b’s bone osteolysis and bone metastasis
program (right). 14-3-3z overexpression in pre-
malignant cells turns off TGF-b’s cytostatic tumor
suppressor function by binding to YAP1 and
sequestering YAP1 in the cytosol, thereby block-
ing YAP1-induced transactivation of 14-3-3s;
conversely, 14-3-3z overexpression in breast
cancer cells turns on TGF-b’smetastasis promoter
function by blocking b-TrCP binding to, and
ubiquitination of, Gli2, thus stabilizing Gli2.
Together, 14-3-3z serves as a molecular switch
turning TGF-b from a tumor suppressor to a
metastasis promoter by altering cellular contextual
determinants of Smads. Solid lines represent
findings described in this study, and dashed lines
represent previously described links.(Yu et al., 2013) in human breast cancer in vivo that were not
recapitulated by 14-3-3z overexpression cell models in vitro.
The crucial role of TGF-b in cancer and other diseases has
motivated numerousefforts ondeveloping therapeutics targeting
the TGF-b pathway, some of which have been tested in the clinic
(Akhurst and Hata, 2012). In phase I and II trials for treating can-
cers that generally overexpress TGF-b, some patients with late-
stage cancers received a marginal benefit from TGF-b inhibitors
(Bogdahn et al., 2011). A major obstacle for effective therapies
targeting the TGF-b pathway has been the complex nature and
opposing roles of TGF-b in different stages of cancer develop-
ment. Thus, understanding the molecular mechanism by which
TGF-b switches its role could guidemore effective TGF-b-target-
ing strategies. In this regard, our findings (Figure 7) suggest that
the TGF-b functional switch by 14-3-3z and the contextual
changes of Smad partners (p53 and Gli2) could be utilized as
biomarkers to aid in selecting appropriate cancer patients who
will benefit from TGF-b antagonists and determining optimal
treatment timing when TGF-b-targeted therapy inhibits cancer.Figure 6. High 14-3-3z Is Associated with TGF-b’s Functional Switch during Breast Cancer De
(A) Representative IHC staining of 14-3-3z, YAP1, 14-3-3s, p21, and Gli2 in normal breast tissue, ADH, DCI
(B–D) Percentage of 14-3-3s (B), p21 (C), and Gli2 (D) IHC score distribution in the indicated breast tissues. U
compare IHC score in ADH, DCIS, and IDC to normal tissue. *p < 0.05, **p < 0.01, ***p < 0.001, by two-taile
(E) The association between 14-3-3z expression and the expression level of nuclear YAP1, 14-3-3s, p21, an
tissue. Number of cases and percent of positive staining in the corresponding group (%) are shown in the table
See also Figure S6.
Cancer Cell 27, 177–192Current therapies targeting the TGF-b
pathway are mainly focused on targeting
TGF-b ligands and/or receptors, e.g.,
TGF-b-neutralizing antibodies, TGF-b re-
ceptor kinase inhibitor, and TGF-b ligandtrap (Akhurst and Hata, 2012). These therapies downmodulate
excessive levels of TGF-b ligands or block the entire TGF-b
signaling cascade. However, a systemic application of anti-TGF-
b therapiesmay bring significant side effects, such aswidespread
inflammation (Shull et al., 1992), autoimmunity, or cardiovascular
defects (Larsson et al., 2001), because TGF-b plays important
roles in various physiological functions. Thus,more specific drugs
that selectively target the downstream signaling in cancer cells
without compromising other systemic homeostatic functions of
TGF-bwouldbesuperior.Our findings in this studysuggest target-
ing TGF-b’s functional switch or the downstream cancer-specific
Smad partners (e.g., Gli2) may be better alternatives to targeting
TGF-b ligandand/or receptor for cancer treatment. Thiswill inspire
the development of drugs to selectively target the TGF-b signaling
in cancer and metastasis without impeding TGF-b physiological
functions innormal tissues. Taken together, our findingsmaysteer
biomarker-guided selection of patients who will most likely
respond to second generation selective therapies to effectively
target TGF-b signaling in the era of personalized medicine.velopment
S, and IDC. Scale bars represent 50 mm.
npaired t test with Welch’s correction was used to
d t test.
d Gli2 in ADH, DCIS, and IDC compared to normal
. p values were determined by chi-square analysis.
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EXPERIMENTAL PROCEDURES
Antibodies and reagents, immunoblotting, cell proliferation assay and BrdU
incorporation assay, immunoprecipitation assay, immunofluorescence stain-
ing, cytoplasm and nuclear protein fractionation, RPPA, cell cycle analysis,
mRNA stability assay, bisulfite genomic sequencing, 5-Aza-20-deoxycytidine
treatment, luciferase reporter assay, chromatin immunoprecipitation (ChIP)
assay, generation of knockdown and overexpression cells, cDNA micro-
array analysis, significance score distribution analysis, expression heatmap,
clinical samples and bioinformatics analysis, RNA extraction, RT-PCR,
triple coculture assay, ubiquitination assay, immunohistochemical staining,
and statistics are described in detail in the Supplemental Experimental
Procedures.
Cell Line and Cell Culture
MCF10A and MDA-MB-231 cell lines and their modified variants were ob-
tained, generated, and cultured as previously described (Khotskaya et al.,
2014; Li et al., 2009; Lu et al., 2009). The 231-1566 cell line is clone 1566 of
the MDA-231-LUC-Met cell line, which was obtained from Dr. Mien-Chie
Hung (Khotskaya et al., 2014). The BoM-1833 cell line was obtained from Dr.
Xiang H.-F. Zhang (Zhang et al., 2009). The MCF12A cell line was obtained
from American Type Culture Collection (ATCC) and cultured in MCF10A me-
dium. The 4T1 cell line was cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 4.5 g/l glucose, L-glutamine, sodium pyruvate,
and 10% FBS. The murine osteoblast cell line MC3T3 was obtained from Dr.
Sue-Hwa Lin (MD Anderson Cancer Center) and maintained in aMEMmedium
with 10% FBS. The murine preosteoclast cell line RAW 264.7 from ATCC was
maintained in DMEMwith 10% FBS for regular culture and supplemented with
30 ng/ml RANKL for osteoclastogenesis assay. For in vitro assays on TGF-b
functions, cells were all treated with fresh medium containing TGF-b (+) or
vehicle () for 2 or 4 hr after removal of the original culture medium.
Bone Metastasis Assay, Bone Tumor Grafts, and Bioluminescence
Analysis
For bone metastasis studies, two different routes of injection were used. For
the intracardiac injection model, 13 105 231-1566 or 53 104 BoM-1833 cells
were injected into the left ventricle of anesthetized female athymic Ncr-nu/nu
mice. For the intratibial injection model, 2 3 105 MDA-MB-231 cells were
injected into the tibia of anesthetized female athymic Ncr-nu/nu mice, or
1 3 103 4T1 sublines were injected into the tibia of anesthetized female
BALB/c mice. Development of bone metastases was monitored by biolumi-
nescence imaging (BLI). Anesthetized mice were intraperitoneally injected
with 75 mg/kg D-luciferin. Bioluminescence images were acquired with a
Xenogen IVIS 200 imaging system. Analysis was performed with live imaging
software by measuring photon flux in the hindlimbs of mice. Data were
normalized to the signal on day 4. Bone metastasis-free survival curves repre-
sent the time point at which each mouse developed bone metastasis by
threshold BLI signals in the hind limbs. All mice used were of the same age
and similar body weight.
X-Ray Analysis and Quantification
Osteolysis was assessed by X-ray radiography. Anesthetized mice were
exposed to X-ray at 40 mm for 1 min and were directly imaged by Carestream
Molecular Imaging software using the Kodak In-Vivo Multispectral Imaging
System. Osteolytic lesions were identified on radiographs as demarcated
radiolucent lesions in the bone and quantified using ImageJ software (NIH).
Hematoxylin and Eosin and Immunohistochemical Staining
Hindlimb bones were excised from mice at the end point of each experiment,
fixed in 10% neutral-buffered formalin, decalcified in 10% EDTA for 2 weeks,
and embedded in paraffin for H&E and immunohistochemical staining. Histo-
morphometric analysis was performed on H&E-stained bone metastasis sam-
ples using the Zeiss Axiovert 200 microscope and AxioVision software version
4.6.3 SP1. Immunohistochemical analysis was performed with heat-induced
antigen retrieval. Primary antibodies used are indicated in the table of the anti-
body list. Biotinylated secondary antibody was used with Vectastain ABC Kit
(Vector Laboratories) and DAB detection kit (Zymed) to reveal the positively
stained cells with nuclei counterstained with hematoxylin.190 Cancer Cell 27, 177–192, February 9, 2015 ª2015 Elsevier Inc.Tissue Specimens
Tissue specimens representing 160 cases were collected at The University of
Texas MD Anderson Cancer Center (UTMDACC) and Southern Medical Uni-
versity (Guangzhou, China), including normal breast tissue, ADH, DCIS, and
IDC (40 cases each). Patient samples were collected and processed in compli-
ance with protocols (LAB10-0995) approved by the UTMDACC Institutional
Review Board and by the Southern Medical University Institutional Review
Board. We used archived samples. At time of tissue collection, informed con-
sent was obtained from all patients.
Animal Experiment
All procedures involving mice and experimental protocols (ACUF ID #07-04-
03437, and ACUF ID #02-12-02331) were approved by the Institutional Animal
Care and Use Committee (IACUC) of University of Texas MD Anderson Cancer
Center.
ACCESSION NUMBERS
The raw and normalized microarray data have been deposited in the GEO
database under accession numbers GSE52032 and GSE52066.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2014.11.025.
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